{"id":"5d004c7bf5bd","type":"article","url":"https://hartvaat.nl/2026/02/23/analytische-validatie-van-een-directe-lp-a-cholesterolbepaling/","title":"Analytische validatie van een directe Lp(a)-cholesterolbepaling","title_en":"Analytical Validation of Direct Lipoprotein(a)-Cholesterol Assay.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"Journal of lipid research","doi":"10.1016/j.jlr.2026.101008","source_url":"https://doi.org/10.1016/j.jlr.2026.101008","authors":["Santica M Marcovina","Spenser Smith","Lizhu Lin","Sotirios Tsimikas"],"significance":4,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Analytical validation of a direct immunocapture ELISA for measuring lipoprotein(a)-cholesterol in human plasma, demonstrating excellent linearity, precision, and specificity. Accurate Lp(a)-C measurement is essential for correct lipid panel interpretation.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een nieuw immunocapture-ELISA voor de directe meting van lipoproteïne(a)-cholesterol is analytisch gevalideerd. De test toont uitstekende lineariteit, precisie en specificiteit. Een nauwkeurige Lp(a)-C-meting is essentieel voor correcte interpretatie van het lipidenprofiel, vooral bij patiënten met sterk verhoogd Lp(a).","abstract_original":"Accurate measurement of lipoprotein(a) cholesterol [Lp(a)-C] may be useful in interpreting the traditional lipid panel, particularly in patients with high Lp(a). We developed and analytically validated in a CLIA certified laboratory a direct immunocapture ELISA for quantifying Lp(a)-C in human plasma using an apolipoprotein(a)-specific monoclonal antibody (LPA4) coupled to magnetic beads. The linearity of the assay was found to be excellent (R2=1.00), with % Bias ranging from 0.3% (upper limit of quantification) to 16.1% (low limit of quantification) and %CV ranging from 3.4% to 16.2%. The analytical measuring range was 0.78 mg/dL to 40.0 mg/dL and the limit of Blank and limit of Detection were 0.02 mg/dL and 0.05 mg/dL, respectively. The intra- and inter-assay coefficients of variation determined on four quality control samples, ranged from 4.9% to 7.6% and from 12.6% to 15.0%, respectively. No interference was observed from hemolysis (up to 0.71 g/dL), bilirubin (up to 10.1 mg/dL), or triglycerides (up to 1082 mg/dL. Lp(a)-C was stable for at least 3 months at -70 °C and through two freeze-thaw cycles. Direct Lp(a)-C correlated strongly with Lp(a) molar (r=0.93, p<0.001) concentration. This study reports the results of the first analytical validation of a direct method to quantify Lp(a)-C, enabling standardized quantification of Lp(a)-C suitable for research studies and clinical trials; additional clinical outcome validation will be required prior to routine clinical implementation."}